Abnova and Japan NIES Collaborate on Transgenic Chicken for Biopharmaceutical Manufacturing

Neihu, Taiwan and Tsukuba, Japan (January 25, 2010).

National Institute for Environmental Studies and the Abnova Corporation have signed a Memorandum of Understanding (MOU) on a joint research relating to the use of chicken primordial germ cell (PGC) for protein and monoclonal antibody production. The technique for obtaining germline chimeras from primordial germ cell has been established in chicken. This collaboration is intended to address the commercial applicability of transgenic chicken as a robust and efficient bio-factory for biopharmaceutical manufacturing which represents an essential bottleneck in cost, time, and scalability in current drug development, and especially in the post NDA, scale-up production prior to commercialization.

As the world's largest manufacturer of reagent antibodies and proteins for the research market, Abnova has taken a key initiative to identify alternative production platforms for the biopharmaceutical market. "The primordial germ cell technology pioneered by Dr. Takashi Kuwana has provided a strong foundation in cell culture and transgenic chicken development to catapult a new era of biopharmaceutical and biogeneric manufacturing in the face of growing list of expired and soon-to-be expired protein drugs and early generation of antibody drug, and a rich pipeline of new monoclonal antibodies currently in clinical trials," stated Wilber Huang, President and CEO of Abnova. "We look forward to working closely with Dr. Kuwana and his team to fully explore all aspects of the technology including its throughput and cost for commercial adaptation." This collaboration provides great opportunity to leverage the resource of both parties coinciding an unparallel opportunity in the biopharmaceutical industry.

"We are pleased to enter into this collaboration with Abnova with expertise and keen market insight on monoclonal antibody and protein application in preclinical discovery and research. Abnova has now taken on the more advanced step of biologic manufacturing with the use of chicken PGC for the creation of germline chimera and then transgenic chicken for large-scale of biopharmaceuticals," says Dr. Takashi Kuwana, Director of the National Institute for Environmental Studies. "Chickens have several advantages over the mammalian transgenic counterparts including high productivity in eggs, efficient breeding, similarity of protein glycosylation, and absence of prion problem. While the feasibility of such approach for individual proteins have been demonstrated in research setting, stable generation of transgenic chicken for a diverse collection of biologics has not been thoroughly investigated. We anticipate valuable data and information to be generated from this collaboration."

Abnova and Japan NIES Collaborate on Transgenic Chicken for Biopharmaceutical Manufacturing

By: Abnova

POST COMMENT

Powder filling machines Macular Degeneration Related To Aging How To Play Wmv On Mac Os X (snow Leopard Included) To get rid of too much acid in the stomach, duedonal ulcers and GERD effectively - Take NEXIUM (Esomeprazole) medication How to Convert PDF to Word in Mac ? Bungie - Angle Seat Valve manufacturer - Machinery parts Do You Know Crusher Machine How About Crusher Machine Gyratory Crusher Machine How To Rip Dvds On Mac Understanding Polypharmacy In The Elderly Mazda Premacy - Angle Seat Valve manufacturer - Water Valves manufacturer Oil Expeller, Single Chamber Oil Expeller, Oil Expeller Machinery